We previously reported that oesophageal squamous cell carcinoma (SCC) had a relatively
high incidence of EGFR and HER-2 overexpression. Thus, anti-HER family targeting may …

Oesophageal cancer is the seventh most common cancer worldwide, with 604 000 new
cases diagnosed in 2020. It is the sixth most common cause of cancer-related mortality, with …

4514 Background: Ramucirumab (Ram) as monotherapy or plus paclitaxel is a proven
second-line option for advanced gastroesophageal adenocarcinoma (GEA). More and more …

The objective of this article was to review clinical trials that used antineoplastic second-line
chemotherapy and/or targeted therapies in patients with esophageal cancer after first-line …

Purpose Squamous cell carcinoma is the main histological subtype of esophageal cancer in
the east Asia. Oxaliplatin and fluorouracil are active agents for esophageal carcinoma. The …

Most patients with oesophageal cancer present with locally advanced or metastatic disease.
In an effort to improve the results of surgery in patients with operable disease, strategies to …

To improve the efficacy and tolerance of the 5-fluorouracil (5-FU)/cisplatin combination in
metastatic esophageal cancer, we designed a new therapeutic schedule, the HLFP regimen …

Abstract Background. The phase II YO28252 study (01590719) examined first-line
onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor …

Background It is unclear if differential chemotherapy effects exist on overall survival (OS),
response rate (RR) and toxicity depending on primary tumour origin [oesophageal versus …

BACKGROUND Recombinant interferon‐α (IFN) augments the cytotoxicity of both 5‐
fluorouracil (5‐FU) and cisplatin in vitro. A Phase II study of 5‐FU and IFN resulted in …